Semaglutide: reported timelines in the literature
A research-supply review of reported timelines for semaglutide across registered studies, covering trial durations, assessment points, and model systems. For laboratory research use only.
Semaglutide: reported timelines in the literature
Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It is also known by the synonyms semaglutide sodium and semaglutide free base, and is classified as an incretin mimetic. The compound has a molecular formula of C187H291N45O59 and a molecular weight of approximately 4113.58 g/mol; its sequence is a modified GLP-1 analogue with a fatty acid side chain. Identifiers include CAS 910463-68-2. In the research literature, timelines for semaglutide are reported across a range of study designs, from 6-month randomised trials to 24-month postoperative assessments, and from in vitro analytical methods to animal models. This page summarises the reported timelines and study durations found in the evidence block, with a focus on registered clinical studies and analytical reviews. All material is for laboratory research use only.
The work centres on the GLP-1 receptor (GLP-1R), a class B G-protein-coupled receptor. Semaglutide binds to and activates this receptor, leading to downstream signalling that is studied in the context of glucose-dependent insulin secretion, gastric emptying, and appetite regulation. The evidence block includes studies in humans with obesity, type 2 diabetes, schizophrenia, alcohol use disorder, and postmenopausal breast cancer, as well as analytical reviews of the compound in pharmaceutical formulations and biological matrices.
Research Studies
Semaglutide and postpartum cardiometabolic risk after gestational diabetes
A registered clinical trial (NCT07797036) is evaluating immediate postpartum semaglutide following a pregnancy complicated by gestational diabetes mellitus (GDM) [1]. This is an effectiveness-implementation Hybrid Type 1 study using a randomised clinical trial design. A total of 226 postpartum individuals with recent GDM are randomised 1:1 to semaglutide or standard postpartum care for a 6-month active treatment phase. The primary effectiveness outcome, development of metabolic syndrome, is assessed at 6 months postpartum. Participants then enter a 6-month maintenance phase, during which semaglutide continuation, discontinuation, or initiation reflects patient and provider decisions. The reported timeline therefore includes a 6-month active phase and a 6-month maintenance phase, with the primary endpoint at 6 months.
Semaglutide and cardiometabolic profile in schizophrenia with metabolic syndrome
A multicentre, double-blind, placebo-controlled randomised trial (NCT07770282) is evaluating adjunctive oral semaglutide 3 mg once daily in patients with schizophrenia on second-generation antipsychotics who have metabolic syndrome [2]. The study assesses whether semaglutide reduces 10-year cardiovascular risk (QRISK3) and improves insulin resistance, lipids, weight, and metabolic biomarkers over 24 weeks compared with placebo, while confirming psychiatric safety and tolerability. The reported timeline for this study is 24 weeks of treatment.
Semaglutide and muscle preservation in older adults starting therapy
A randomised, double-blind, placebo-controlled trial (NCT07760948) is evaluating whether daily calcium beta-hydroxy-beta-methylbutyrate (calcium-HMB) plus vitamin D3 preserves muscle mass, physical function, and resting metabolism in adults aged 65 to 85 years with type 2 diabetes who are newly starting semaglutide as part of usual clinical care [3]. Participants receive calcium-HMB plus vitamin D3 or matching placebo for approximately 6 months. The primary outcome is change in appendicular lean mass measured by dual-energy X-ray absorptiometry from baseline to month 6. Secondary assessments include body composition, muscle strength, physical performance, gait, physical activity, and resting metabolic rate. The reported timeline is approximately 6 months.
Semaglutide and switching to zovaglutide in adults with obesity
A study (NCT07812597) is evaluating the safety and tolerability of continuing treatment with zovaglutide injection following titration to 2.4 mg semaglutide injection in adult participants with obesity [4]. The main purpose is to assess safety and tolerability during the switch. The evidence block does not specify the duration of this study beyond the titration and continuation phases.
Semaglutide dose effects on metabolic and stress hormones, craving, and alcohol use
A study (NCT07772960) is examining two doses of semaglutide, 1.0 mg and 2.0 mg, versus placebo in patients with alcohol use disorder (AUD) and obesity (Ob) to assess whether these doses improve alcohol craving, stress, and alcohol use outcomes [5]. The evidence block does not specify the duration of this study.
Semaglutide and zenagamtide in excess body weight
A research study (NCT07668414) is investigating how well the medicine zenagamtide helps people with excess body weight lose weight compared to semaglutide [6]. The purpose is to find out if zenagamtide is safe and effective for treating participants who have excess body weight compared to treatment with semaglutide. The evidence block does not specify the duration of this study.
Semaglutide and early reinitiation post-sleeve gastrectomy in youth
A Phase 3a, randomised, parallel-controlled trial (NCT06934655) is comparing early reinitiation of semaglutide, starting two weeks after sleeve gastrectomy, to standard care (no pharmacotherapy following surgery) in 150 youth with severe obesity who have been on semaglutide 2.4 mg weekly for at least 3 months prior to surgery [7]. Participants are randomised to either semaglutide 2.4 mg weekly or standard care for 24 months. Primary, secondary, and tertiary outcomes are assessed at multiple time points: 1-month, day of surgery, and 1-, 3-, 6-, 9-, 12-, 18-, and 24-months postoperatively. The reported timeline includes a 24-month treatment period with assessments at the listed intervals.
Semaglutide and structured lifestyle support in postmenopausal breast cancer survivors
A phase IV trial (NCT07769047) is studying whether adding semaglutide to structured lifestyle support improves heart and blood vessel health in postmenopausal obese breast cancer survivors (BCS) who are taking an aromatase inhibitor [8]. In this population, obesity raises the risk of heart and blood vessel problems. The structured lifestyle support includes counselling on nutrition and physical activity. The evidence block does not specify the duration of this trial.
Semaglutide and analytical methods in pharmaceutical formulations and biological matrices
A comprehensive review reports that semaglutide is a potent long-acting GLP-1 receptor agonist with therapeutic efficacy for type 2 diabetes and obesity, and that its widespread clinical use has increased demand for analytical techniques to identify semaglutide in pharmaceutical formulations and biological matrices [9]. This reference-only source supports the characterisation of semaglutide as a long-acting GLP-1 receptor agonist and the need for analytical methods, but does not provide a timeline for clinical effects.
Semaglutide and treatment patterns among adult users in Denmark
A community pharmacy-based cross-sectional survey investigated semaglutide treatment patterns among Danish adult users for weight management [10]. The survey was conducted across 28 Danish community pharmacies between March and May 2025. The evidence block does not specify the duration of individual treatment or follow-up beyond the survey period.
Semaglutide and neuropsychiatric outcomes
A review reports that neuropsychiatric safety concerns, including depression and suicidal ideation, have emerged during the expanding clinical use of incretin-based therapies for type 2 diabetes mellitus and obesity, but whether risks differ across successive generations of incretin-based therapies remains uncertain [11]. This reference-only source supports the context of safety monitoring but does not provide a timeline.
Semaglutide and gallbladder-related adverse events
A pooled analysis of placebo-controlled STEP trials reports on gallbladder-related adverse events with semaglutide 2.4 mg [12]. This reference-only source supports the context of adverse event monitoring but does not provide a timeline.
Reported timelines at a glance
| Study identifier | Population | Reported timeline |
|---|---|---|
| NCT07797036 [1] | Postpartum individuals with recent GDM | 6-month active phase; 6-month maintenance phase; primary outcome at 6 months |
| NCT07770282 [2] | Patients with schizophrenia and metabolic syndrome | 24 weeks |
| NCT07760948 [3] | Adults aged 65–85 with type 2 diabetes starting semaglutide | Approximately 6 months |
| NCT07812597 [4] | Adults with obesity switching to zovaglutide | Not specified in evidence block |
| NCT07772960 [5] | Patients with alcohol use disorder and obesity | Not specified in evidence block |
| NCT07668414 [6] | Participants with excess body weight | Not specified in evidence block |
| NCT06934655 [7] | Youth with severe obesity post-sleeve gastrectomy | 24 months; assessments at 1, 3, 6, 9, 12, 18, 24 months postoperatively |
| NCT07769047 [8] | Postmenopausal obese breast cancer survivors on aromatase inhibitors | Not specified in evidence block |
If you are reading this for personal health reasons
This material is sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes
- [2] Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome
- [3] HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting Semaglutide
- [4] A Study Evaluating Safety and Tolerability of Switching From Semaglutide to Zovaglutide in Adults With Obesity (HORIZON-SWITCH-SZ)
- [5] Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes
- [6] A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide
- [7] Early Reinitiation of Semaglutide Post-Sleeve Gastrectomy in Youth
- [8] Semaglutide and Structured Lifestyle Support to Improve Heart and Blood Vessel Health in Postmenopausal Obese Breast Cancer Survivors Taking Aromatase Inhibitors
- [9] Analytical methods for the determination of semaglutide in pharmaceutical formulations and biological matrices: A comprehensive review.
- [10] Treatment Patterns and Experienced Effects of Semaglutide for Weight Management Among Adult Users in Denmark: A Community Pharmacy-Based Cross-Sectional Survey.
- [11] Neuropsychiatric Outcomes With Tirzepatide, Semaglutide, and Other GLP-1 Receptor Agonists.
- [12] Gallbladder-Related Adverse Events With Semaglutide 2.4 mg: Pooled Analysis of Placebo-Controlled STEP Trials.